Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Sep 29;9(9):CD011790.
doi: 10.1002/14651858.CD011790.pub2.

Pregabalin for pain in fibromyalgia in adults

Sheena Derry  1 , Malene Cording, Philip J Wiffen, Simon Law, Tudor Phillips, R Andrew Moore
Affiliations
Review

Pregabalin for pain in fibromyalgia in adults

Sheena Derry et al. Cochrane Database Syst Rev. .

Abstract

Background: This review updates part of an earlier Cochrane review on 'Pregabalin for acute and chronic pain in adults' (Moore 2009), and considers only fibromyalgia pain.Antiepileptic drugs have been used in pain management since the 1960s. Pregabalin is an antiepileptic drug also used in management of chronic pain conditions, including fibromyalgia. Pain response with pregabalin is associated with major benefits for other symptoms, and improved quality of life and function in people with chronic painful conditions.

Objectives: To assess the analgesic efficacy and adverse events of pregabalin for pain in fibromyalgia in adults, compared with placebo or any active comparator.

Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and EMBASE for randomised controlled trials from inception to May 2009 for the original review and to 16 March 2016 for this update. We also searched the reference lists of retrieved studies and reviews, and online clinical trial registries.

Selection criteria: We included randomised, double-blind trials of eight weeks' duration or longer, comparing pregabalin with placebo or another active treatment for relief of pain in fibromyalgia, and reporting on the analgesic effect of pregabalin, with subjective pain assessment by the participant.

Data collection and analysis: Two review authors independently extracted data and assessed trial quality and potential bias. Primary outcomes were participants with moderate pain relief (at least 30% pain relief over baseline or much or very much improved on Patient Global Impression of Change scale (PGIC)) or substantial pain relief (at least 50% pain relief over baseline or very much improved on PGIC). Where pooled analysis was possible, we used dichotomous data to calculate risk ratio and number needed to treat (NNT), using standard methods. We assessed the quality of the evidence using GRADE (Grading of Recommendations Assessment, Development and Evaluation) and created 'Summary of findings' tables.

Main results: Our searches identified two new published studies with classic design, and one new published study with an enriched enrolment randomised withdrawal (EERW) design.We included eight studies. Five (3283 participants) had a classic design in which participants were randomised at the start of the study to pregabalin (150, 300, 450, or 600 mg daily) or placebo, with assessment after 8 to 13 weeks of stable treatment. No studies included active comparators. Studies had low risk of bias, except that the last observation carried forward (LOCF) imputation method used in analyses of the primary outcomes could overestimate treatment effect.Pregabalin increased the number of participants experiencing substantial benefit (at least 50% pain intensity reduction after 12 or 13 weeks' stable treatment (450 mg: RR 1.8, 95% CI 1.4 to 2.1, 1874 participants, 5 studies, high quality evidence)). Substantial benefit with pregabalin 300 to 600 mg was experienced by about 14% of participants with placebo, but about 9% more with pregabalin 300 to 600 mg (22% to 24%) (high quality evidence). Pregabalin increased the number of participants experiencing moderate benefit (at least 30% pain intensity reduction after 12 or 13 weeks' stable treatment) (450 mg: RR 1.5, 95% CI (1.3 to 1.7), 1874 participants, 5 studies, high quality evidence). Moderate benefit with pregabalin 300 to 600 mg was experienced by about 28% of participants with placebo, but about 11% more with pregabalin 300 to 600 mg (39% to 43%) (high quality evidence). A similar magnitude of effect was found using PGIC of 'very much improved' and 'much or very much improved'. NNTs for these outcomes ranged between 7 and 14 (high quality evidence).A small study (177 participants) compared nightly with twice-daily pregabalin, and concluded there was no difference in effect.Two studies (1492 participants began initial dose titration, 687 participants randomised) had an EERW design in which those with good pain relief after titration were randomised, double blind, to continuing the effective dose (300 to 600 mg pregabalin daily) or a short down-titration to placebo for 13 or 26 weeks. We calculated the outcome of maintained therapeutic response (MTR) without withdrawal, equivalent to a moderate benefit. Of those randomised, 40% had MTR with pregabalin and 20% with placebo (high quality evidence). The NNT was 5, but normalised to the starting population tested it was 12. About 10% of the initial population would have achieved the MTR outcome, similar to the result from studies of classic design. MTR had no imputation concerns.The majority (70% to 90%) of participants in all treatment groups experienced adverse events. Specific adverse events were more common with pregabalin than placebo, in particular dizziness, somnolence, weight gain, and peripheral oedema, with number needed to harm of 3.7, 7.4, 18, and 19 respectively for all doses combined (high quality evidence). Serious adverse events did not differ between active treatment groups and placebo (very low quality evidence). Withdrawals for any reason were more common with pregabalin than placebo only with the 600 mg dose in studies of classic design. Withdrawals due to adverse events were about 10% higher with pregabalin than placebo, but withdrawals due to lack of efficacy were about 6% lower (high quality evidence).

Authors' conclusions: Pregabalin 300 to 600 mg produces a major reduction in pain intensity over 12 to 26 weeks with tolerable adverse events for a small proportion of people (about 10% more than placebo) with moderate or severe pain due to fibromyalgia. The degree of pain relief is known to be accompanied by improvements in other symptoms, quality of life, and function. These results are similar to other effective medicines in fibromyalgia (milnacipran, duloxetine).

PubMed Disclaimer

Conflict of interest statement

SD: none known.

MC: none known.

PW: none known.

SL: none known; SL is a specialist pain physician and manages patients with fibromyalgia.

TP: none known; TP is a specialist pain physician and manages patients with fibromyalgia.

RAM has received grant support from RB relating to individual patient level analyses of trial data on ibuprofen in acute pain and the effects of food on drug absorption of analgesics (2013), and from Grünenthal relating to individual patient level analyses of trial data regarding tapentadol in osteoarthritis and back pain (2015). He has received honoraria for attending boards with Menarini concerning methods of analgesic trial design (2014), with Novartis (2014) about the design of network meta‐analyses, and RB on understanding pharmacokinetics of drug uptake (2015).

Figures

1
1
Study flow diagram.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
4
4
Forest plot of comparison: 1 Pregabalin versus placebo, outcome: 1.2 At least 50% pain relief.
5
5
Forest plot of comparison: 1 Pregabalin versus placebo, outcome: 1.3 Much or very much improved.
1.1
1.1. Analysis
Comparison 1 Pregabalin versus placebo (studies of classic design), Outcome 1 At least 30% pain relief.
1.2
1.2. Analysis
Comparison 1 Pregabalin versus placebo (studies of classic design), Outcome 2 At least 50% pain relief.
1.3
1.3. Analysis
Comparison 1 Pregabalin versus placebo (studies of classic design), Outcome 3 Much or very much improved.
1.4
1.4. Analysis
Comparison 1 Pregabalin versus placebo (studies of classic design), Outcome 4 Very much improved.
1.5
1.5. Analysis
Comparison 1 Pregabalin versus placebo (studies of classic design), Outcome 5 All‐cause withdrawal.
1.6
1.6. Analysis
Comparison 1 Pregabalin versus placebo (studies of classic design), Outcome 6 Adverse event withdrawal.
1.7
1.7. Analysis
Comparison 1 Pregabalin versus placebo (studies of classic design), Outcome 7 Lack of efficacy withdrawal.
1.8
1.8. Analysis
Comparison 1 Pregabalin versus placebo (studies of classic design), Outcome 8 Participants with at least one adverse event.
1.9
1.9. Analysis
Comparison 1 Pregabalin versus placebo (studies of classic design), Outcome 9 Participants with at least one serious adverse event.
1.10
1.10. Analysis
Comparison 1 Pregabalin versus placebo (studies of classic design), Outcome 10 Participants experiencing somnolence.
1.11
1.11. Analysis
Comparison 1 Pregabalin versus placebo (studies of classic design), Outcome 11 Participants experiencing dizziness.
1.12
1.12. Analysis
Comparison 1 Pregabalin versus placebo (studies of classic design), Outcome 12 Participants experiencing weight gain.
1.13
1.13. Analysis
Comparison 1 Pregabalin versus placebo (studies of classic design), Outcome 13 Participants experiencing peripheral oedema.
2.1
2.1. Analysis
Comparison 2 Pregabalin versus placebo (EERW studies), Outcome 1 Maintenance of therapeutic response.
2.2
2.2. Analysis
Comparison 2 Pregabalin versus placebo (EERW studies), Outcome 2 All‐cause withdrawal.
2.3
2.3. Analysis
Comparison 2 Pregabalin versus placebo (EERW studies), Outcome 3 Participants with at least one adverse event.
See this image and copyright information in PMC

Comment in

References

References to studies included in this review

Arnold 2008 {published data only}
    1. Arnold LM, Russell IJ, Diri EW, Duan WR, Young JP Jr, Sharma U, et al. A 14‐week, randomized, double‐blinded, placebo‐controlled monotherapy trial of pregabalin in patients with fibromyalgia. Journal of Pain 2008;9(9):792‐805. [CTG: NCT00230776; DOI: 10.1016/j.jpain.2008.03.013] - DOI - PubMed
Arnold 2014 {published data only}
    1. Arnold LM, Arsenault P, Huffman C, Patrick JL, Messig M, Chew ML, et al. Once daily controlled‐release pregabalin in the treatment of patients with fibromyalgia: a phase III, double‐blind, randomized withdrawal, placebo‐controlled study. Current Medical Research and Opinion 2014;30(10):2069‐83. [CTG: NCT01271933; DOI: 10.1185/03007995.2014.928275] - DOI - PubMed
Crofford 2005 {published data only}
    1. Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Pregabalin 1008‐105 Study Group, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double‐blind, placebo‐controlled trial. Arthritis and Rheumatism 2005;52(4):1264‐73. [DOI: 10.1002/art.20983] - DOI - PubMed
Crofford 2008 {published data only}
    1. Crofford LJ, Mease PJ, Simpson SL, Young JP Jr, Martin SA, Haig GM, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6‐month, double‐blind, placebo‐controlled trial with pregabalin. Pain 2008;136(3):419‐31. [DOI: 10.1016/j.pain.2008.02.027] - DOI - PubMed
    1. Pauer L, Atkinson G, Murphy TK, Petersel D, Zeiher B. Long‐term maintenance of response across multiple fibromyalgia symptom domains in a randomized withdrawal study of pregabalin. Clinical Journal of Pain 2012;28(7):609‐14. [CTG: NCT00151489; DOI: 10.1097/AJP.0b013e31823dd315] - DOI - PubMed
Mease 2008 {published data only}
    1. Mease PJ, Russell IJ, Arnold LM, Florian H, Young JP Jr, Martin SA, et al. A randomized, double‐blind, placebo‐controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. Journal of Rheumatology 2008;35(3):502‐14. [CTG: NCT00645398] - PubMed
Nasser 2014 {published data only}
    1. Nasser K, Kivitz AJ, Maricic MJ, Silver DS, Silverman SL. Twice daily versus once nightly dosing of pregabalin for fibromyalgia: a double‐blind randomized clinical trial of efficacy and safety. Arthritis Care and Research 2014;66(2):293‐300. [CTG: NCT01226667; DOI: 10.1002/acr.22111] - DOI - PubMed
Ohta 2012 {published data only}
    1. Ohta H, Oka H, Usui C, Ohkura M, Suzuki M, Nishioka K. A randomized, double‐blind, multicenter, placebo‐controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia. Arthritis Research and Therapy 2012;14(5):R217. [CTG: NCT00830167; DOI: 10.1186/ar4056] - DOI - PMC - PubMed
Pauer 2011 {published data only}
    1. A 14‐week, randomized, double‐blind, placebo‐controlled trial of pregabalin twice daily in patients with fibromyalgia. PhRMA Web Synopsis 7 March 2008.
    1. Pauer L, Winkelmann A, Arsenault P, Jespersen A, Whelan L, Atkinson G, et al. An international, randomized, double‐blind, placebo‐controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia. Journal of Rheumatology 2011;38(12):2643‐52. [CTG: NCT00333866; DOI: 10.3899/jrheum.110569] - DOI - PubMed

References to studies excluded from this review

Arnold 2012 {published data only}
    1. Arnold LM, Emir B, Murphy TK, Zeiher BG, Pauer L, Scott G, et al. Safety profile and tolerability of up to 1 year of pregabalin treatment in 3 open‐label extension studies in patients with fibromyalgia. Clinical Therapeutics 2012;34(5):1092‐102. [DOI: 10.1016/j.clinthera.2012.03.003] - DOI - PubMed
Arnold 2015 {published data only}
    1. Arnold LM, Sarzi‐Puttini P, Arsenault P, Khan T, Bhadra Brown P, Clair A, et al. Efficacy and safety of pregabalin in patients with fibromyalgia and comorbid depression taking concurrent antidepressant medication: a randomized, placebo‐controlled study. Journal of Rheumatology 2015;42(7):1237‐44. [DOI: 10.3899/jrheum.141196] - DOI - PubMed
    1. NCT01432236. A phase 3b multicenter, double‐blind, randomized, placebo‐controlled, 2‐way crossover study of pregabalin in the treatment of fibromyalgia with concurrent antidepressant therapy for comorbid depression. clinicaltrials.gov/ct2/show/NCT01432236 (accessed 16 March 2016).
Byon 2010 {published data only}
    1. Byon W, Ouellet D, Chew M, Ito K, Burger P, Pauer L, et al. Exposure‐response analyses of the effects of pregabalin in patients with fibromyalgia using daily pain scores and patient global impression of change. Journal of Clinical Pharmacology 2010;50(7):803‐15. [DOI: 10.1177/0091270009352187] - DOI - PubMed
Emir 2010 {published data only}
    1. Emir B, Murphy TK, Petersel DL, Whalen E. Treatment response to pregabalin in fibromyalgia pain: effect of patient baseline characteristics. Expert Opinion on Pharmacotherapy 2010;11(14):2275‐80. [DOI: 10.1517/14656566.2010.509717] - DOI - PubMed
NCT00760474 {unpublished data only}
    1. NCT00760474. A double‐blind, placebo‐controlled cross‐over study in fibromyalgia subjects to examine effects of pregabalin on brain response to mechanical pain as assessed by functional magnetic resonance imaging, proton magnetic resonance spectroscopy and subjective ratings. clinicaltrials.gov/ct2/show/NCT00760474 (accessed 16 March 2016).
NCT01268631 {unpublished data only}
    1. NCT01268631. Mechanism‐based choice of therapy: can treatments success in fibromyalgia patients be coupled to psychophysical pain modulation profile?. clinicaltrials.gov/ct2/show/NCT01268631 (accessed 16 March 2016).
NCT01904097 {unpublished data only}
    1. NCT01904097. Study of the brain with optic functional neuroimaging in patients with chronic pain using transcranial direct current stimulation. clinicaltrials.gov/ct2/show/NCT01904097 (accessed 16 March 2016).
Ohta 2013 {published data only}
    1. Ohta H, Oka H, Usui C, Ohkura M, Suzuki M, Nishioka K. An open‐label long‐term phase III extension trial to evaluate the safety and efficacy of pregabalin in Japanese patients with fibromyalgia. Modern Rheumatology/the Japan Rheumatism Association 2013;23(6):1108‐15. [DOI: 10.1007/s10165-012-0803-x] - DOI - PubMed
Ramzy 2016 {published data only}
    1. Ramzy EA. Comparative efficacy of newer antidepressants in combination with pregabalin for fibromyalgia syndrome: a controlled, randomized study. Pain Practice 2016;Feb 19. [DOI: 10.1111/papr.12409] - DOI - PubMed
Roth 2012 {published data only}
    1. Roth T, Lankford DA, Bhadra P, Whalen E, Resnick EM. Effect of pregabalin on sleep in patients with fibromyalgia and sleep maintenance disturbance: a randomized, placebo‐controlled, 2‐way crossover polysomnography study. Arthritis Care and Research 2012;64(4):597‐606. [DOI: 10.1002/acr.21595] - DOI - PubMed
Russell 2009 {published data only}
    1. Russell IJ, Crofford LJ, Leon T, Cappelleri JC, Bushmakin AG, Whalen E, et al. The effects of pregabalin on sleep disturbance symptoms among individuals with fibromyalgia syndrome. Sleep Medicine 2009;10(6):604‐10. [DOI: 10.1016/j.sleep.2009.01.009] - DOI - PubMed

References to ongoing studies

NCT01387607 {unpublished data only}
    1. NCT01387607. A 14‐week, randomized, double‐blind placebo‐controlled study for pregabalin in patients with fibromyalgia. clinicaltrials.gov/ct2/show/NCT01387607 (accessed 16 March 2016). [A0081241]
NCT02146430 {unpublished data only}
    1. NCT02146430. A randomized, double‐blind, placebo‐ and active‐controlled study of DS‐5565 for treatment of pain associated with fibromyalgia. clinicaltrials.gov/ct2/show/NCT02146430 (accessed 16 March 2016). [Sponsor ID: DS5565‐A‐E309]
NCT02187159 {unpublished data only}
    1. NCT02187159. A randomized, double‐blind, placebo‐ and active‐controlled study of DS‐5565 for treatment of pain associated with fibromyalgia. clinicaltrials.gov/ct2/show/NCT02187159 (accessed 16 March 2016). [Sponsor ID: DS5565‐A‐E311]

Additional references

Arnold 2013
    1. Arnold LM, Fan J, Russell IJ, Yunus MB, Khan MA, Kushner I, et al. The fibromyalgia family study: a genome‐wide linkage scan study. Arthritis and Rheumatism 2013;65(4):1122‐8. [DOI: 10.1002/art.37842] - DOI - PMC - PubMed
Bennett 2007
    1. Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskeletal Disorders 2007;8:27. [DOI: 10.1186/1471-2474-8-27] - DOI - PMC - PubMed
Bockbrader 2010
    1. Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clinical Pharmacokinetics 2010;49(10):661‐9. [DOI: 10.2165/11536200-000000000-00000] - DOI - PubMed
Bradley 2009
    1. Bradley LA. Pathophysiology of fibromyalgia. The American Journal of Medicine 2009;122:S22‐30. [DOI: 10.1016/j.amjmed.2009.09.008] - DOI - PMC - PubMed
Choi 2010
    1. Choi CJ, Knutsen R, Oda K, Fraser GE, Knutsen SF. The association between incident self‐reported fibromyalgia and nonpsychiatric factors: 25‐years follow‐up of the Adventist Health Study. Journal of Pain 2010;11:994‐1003. [DOI: 10.1016/j.jpain.2010.01.267] - DOI - PMC - PubMed
Clauw 2014
    1. Clauw DJ. Fibromyalgia: a clinical review. JAMA 2014;311:1547‐55. [DOI: 10.1001/jama.2014.3266] - DOI - PubMed
Collins 1997
    1. Collins SL, Moore RA, McQuay HJ. The visual analogue pain intensity scale: what is moderate pain in millimetres?. Pain 1997;72(1‐2):95‐7. [DOI: 10.1016/S0304-3959(97)00005-5] - DOI - PubMed
Conaghan 2015
    1. Conaghan PG, Peloso PM, Everett SV, Rajagopalan S, Black CM, Mavros P, et al. Inadequate pain relief and large functional loss among patients with knee osteoarthritis: evidence from a prospective multinational longitudinal study of osteoarthritis real‐world therapies. Rheumatology (Oxford) 2015;54(2):270‐7. [DOI: 10.1093/rheumatology/keu332] - DOI - PMC - PubMed
Cording 2015
    1. Cording M, Derry S, Phillips T, Moore RA, Wiffen PJ. Milnacipran for pain in fibromyalgia in adults. Cochrane Database of Systematic Reviews 2015, Issue 10. [DOI: 10.1002/14651858.CD008244.pub3] - DOI - PMC - PubMed
Dechartres 2013
    1. Dechartres A, Trinquart L, Boutron I, Ravaud P. Influence of trial sample size on treatment effect estimates: meta‐epidemiological study. BMJ 2013;346:f2304. [DOI: 10.1136/bmj.f2304] - DOI - PMC - PubMed
Dechartres 2014
    1. Dechartres A, Altman DG, Trinquart L, Boutron I, Ravaud P. Association between analytic strategy and estimates of treatment outcomes in meta‐analyses. JAMA 2014;312(6):623‐30. [DOI: 10.1001/jama.2014.8166] - DOI - PubMed
Dworkin 2008
    1. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain 2008;9(2):105‐21. [DOI: 10.1016/j.jpain.2007.09.005] - DOI - PubMed
Eich 2012
    1. Eich W, Häuser W, Arnold B, Bernardy K, Brückle W, Eidmann U, et al. Fibromyalgia syndrome. General principles and coordination of clinical care and patient education. Schmerz 2012;26:268‐75. [DOI: 10.1007/s00482-012-1167-z] - DOI - PubMed
EMC 2016
    1. Pregabalin. Electronic Medicines Compendium. www.medicines.org.uk/emc/medicine/14651 (accessed 16 March 2016).
Fitzcharles 2013
    1. Fitzcharles MA, Ste‐Marie PA, Goldenberg DL, Pereira JX, Abbey S, Choinière M, et al. 2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary. Pain Research Management 2013;18:119‐26. [PUBMED: 23748251] - PMC - PubMed
Forseth 1999
    1. Forseth KO, Husby G, Gran JT, Førre O. Prognostic factors for the development of fibromyalgia in women with self‐reported musculoskeletal pain. A prospective study. Journal of Rheumatology 1999;26:2458‐67. [PUBMED: 10555910] - PubMed
Guyatt 2011
    1. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence – inconsistency. Journal of Clinical Epidemiology 2011;64(12):1294‐302. [DOI: 10.1016/j.jclinepi.2011.03.017] - DOI - PubMed
Guyatt 2013a
    1. Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso‐Coello P, et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology 2013;66(2):151‐7. [DOI: 10.1016/j.jclinepi.2012.01.006] - DOI - PubMed
Guyatt 2013b
    1. Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al. GRADE guidelines: 12. Preparing summary of findings tables‐binary outcomes. Journal of Clinical Epidemiology 2013;66(2):158‐72. [DOI: 10.1016/j.jclinepi.2012.01.012] - DOI - PubMed
Higgins 2011
    1. Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available at www.cochrane‐handbook.org.
Hoffman 2010
    1. Hoffman DL, Sadosky A, Dukes EM, Alvir J. How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy?. Pain 2010;149(2):194‐201. [DOI: 10.1016/j.pain.2009.09.017] - DOI - PubMed
Häuser 2008
    1. Häuser W, Arnold B, Eich W, Felde E, Flügge C, Henningsen P, et al. 13. Management of fibromyalgia syndrome ‐ an interdisciplinary evidence‐based guideline. German Medical Science 2008;6:Doc 14. [PUBMED: 19675740] - PMC - PubMed
Häuser 2010
    1. Häuser W, Petzke F, Sommer C. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. Journal of Pain 2010;11(6):505‐21. [DOI: 10.1016/j.jpain.2010.01.002] - DOI - PubMed
Häuser 2011
    1. Häuser W, Kosseva M, Üceyler N, Klose P, Sommer C. Emotional, physical, and sexual abuse in fibromyalgia syndrome: a systematic review with meta‐analysis. Arthritis Care & Research 2011;63:808‐20. [DOI: 10.1002/acr.20328] - DOI - PubMed
Häuser 2013a
    1. Häuser W, Galek A, Erbslöh‐Möller B, Köllner V, Kühn‐Becker H, Langhorst J, et al. Posttraumatic stress disorder in fibromyalgia syndrome: prevalence, temporal relationship between posttraumatic stress and fibromyalgia symptoms, and impact on clinical outcome. Pain 2013;154:1216‐23. [DOI: 10.1016/j.pain.2013.03.034] - DOI - PubMed
Häuser 2013b
    1. Häuser W, Urrútia G, Tort S, Uçeyler N, Walitt B. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database of Systematic Reviews 2013, Issue 1. [DOI: 10.1002/14651858.CD010292] - DOI - PubMed
Häuser 2014
    1. Häuser W, Henningsen P. Fibromyalgia syndrome ‐ a somaform disorder?. European Journal of Pain 2014;18:1052‐9. [DOI: 10.1002/j.1532-2149.2014.00453.x] - DOI - PubMed
Häuser 2015
    1. Häuser W, Ablin J, Fitzcharles MA, Littlejohn G, Luciano JV, Usui C, et al. Fibromyalgia. Nature Reviews Disease Primers 2015;1:Article number: 15022. [DOI: 10.1038/nrdp.2015.22] - DOI - PubMed
Jadad 1996
    1. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1‐12. [DOI: ] - PubMed
Kalso 2013
    1. Kalso E, Aldington DJ, Moore RA. Drugs for neuropathic pain. BMJ 2013;347:f7339. [DOI: 10.1136/bmj.f7339] - DOI - PubMed
Kim 2013
    1. Kim SC, Landon JE, Solomon DH. Clinical characteristics and medication uses among fibromyalgia patients newly prescribed amitriptyline, duloxetine, gabapentin, or pregabalin. Arthritis Care and Research 2013;65(11):1813‐9. [DOI: 10.1002/j.1532-2149.2012.00234.x] - DOI - PMC - PubMed
Koroschetz 2011
    1. Koroschetz J, Rehm SE, Gockel U, Brosz M, Freynhagen R, Tölle TR, et al. Fibromyalgia and neuropathic pain ‐ differences and similarities. A comparison of 3057 patients with diabetic painful neuropathy and fibromyalgia. BMC Neurology 2011;11:55. [DOI: 10.1186/1471-2377-11-55] - DOI - PMC - PubMed
L'Abbé 1987
    1. L'Abbé KA, Detsky AS, O'Rourke K. Meta‐analysis in clinical research. Annals of Internal Medicine 1987;107(2):224‐33. [DOI: 10.7326/0003-4819-107-2-224] - DOI - PubMed
Lange 2010
    1. Lange M, Petermann F. Influence of depression on fibromyalgia: A systematic review. Schmerz 2010;24:326‐33. [DOI: 10.1007/s00482-010-0937-8] - DOI - PubMed
Lee 2012
    1. Lee YH, Choi SJ, Ji JD, Song GG. Candidate gene studies of fibromyalgia: a systematic review and meta‐analysis. Rheumatology International 2012;32:417‐26. [DOI: 10.1007/s00296-010-1678-9] - DOI - PubMed
Lunn 2014
    1. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD007115.pub3] - DOI - PMC - PubMed
Macfarlane 2016
    1. Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, Häuser W, Fluß E, et al. EULAR revised recommendations for the management of fibromyalgia. Annals of the Rheumatic Diseases 2016;Epub ahead of print. [DOI: 10.1136/annrheumdis-2016-209724] - DOI - PubMed
Mansfield 2016
    1. Mansfield KE, Sim J, Jordan JL, Jordan KP. A systematic review and meta‐analysis of the prevalence of chronic widespread pain in the general population. Pain 2016;157(1):55‐64. [DOI: 10.1097/j.pain.0000000000000314] - DOI - PMC - PubMed
McQuay 1998
    1. McQuay H, Moore R. An Evidence‐based Resource for Pain Relief. Oxford: Oxford University Press, 1998. [ISBN: 0‐19‐262718‐X]
McQuay 2008
    1. McQuay HJ, Derry S, Moore RA, Poulain P, Legout V. Enriched enrolment with randomised withdrawal (EERW): Time for a new look at clinical trial design in chronic pain. Pain 2008;135(3):217‐20. [DOI: 10.1016/j.pain.2008.01.014] - DOI - PubMed
Mills 2015
    1. Mills EJ, Ayers D, Chou R, Thorlund K. Are current standards of reporting quality for clinical trials sufficient in addressing important sources of bias?. Contemporary Clinical Trials 2015;45(Pt A):2‐7. [DOI: 10.1016/j.cct.2015.07.019] - DOI - PubMed
Moore 1998
    1. Moore RA, Gavaghan D, Tramèr MR, Collins SL, McQuay HJ. Size is everything ‐ large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998;78(3):209‐16. [DOI: 10.1016/S0304-3959(98)00140-7] - DOI - PubMed
Moore 2008
    1. Moore RA, Barden J, Derry S, McQuay HJ. Managing potential publication bias. In: McQuay HJ, Kalso E, Moore RA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15‐24. [ISBN: 978–0–931092–69–5]
Moore 2010a
    1. Moore RA, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S, et al. "Evidence" in chronic pain ‐ establishing best practice in the reporting of systematic reviews. Pain 2010;150(3):386‐9. [DOI: 10.1016/j.pain.2010.05.011] - DOI - PubMed
Moore 2010b
    1. Moore RA, Straube S, Paine J, Phillips CJ, Derry S, McQuay HJ. Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain 2010;149(2):360‐4. [DOI: 10.1016/j.pain.2010.02.039] - DOI - PubMed
Moore 2010c
    1. Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H. Responder analysis for pain relief and numbers needed to treat in a meta‐analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases 2010;69(2):374‐9. [DOI: 10.1136/ard.2009.107805] - DOI - PMC - PubMed
Moore 2010d
    1. Moore RA, Smugar SS, Wang H, Peloso PM, Gammaitoni A. Numbers‐needed‐to‐treat analyses ‐ do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo‐controlled chronic low back pain trials. Pain 2010;151(3):592‐7. [DOI: 10.1016/j.pain.2010.07.013] - DOI - PubMed
Moore 2011a
    1. Moore RA, Straube S, Paine J, Derry S, McQuay HJ. Minimum efficacy criteria for comparisons between treatments using individual patient meta‐analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction. Pain 2011;152(5):982‐9. [DOI: 10.1016/j.pain.2010.11.030] - DOI - PubMed
Moore 2011b
    1. Moore RA, Mhuircheartaigh RJ, Derry S, McQuay HJ. Mean analgesic consumption is inappropriate for testing analgesic efficacy in post‐operative pain: analysis and alternative suggestion. European Journal of Anaesthesiology 2011;28(6):427‐32. [DOI: 10.1097/EJA.0b013e328343c569] - DOI - PubMed
Moore 2012a
    1. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD008242.pub2] - DOI - PubMed
Moore 2012b
    1. Moore RA, Straube S, Eccleston C, Derry S, Aldington D, Wiffen P, et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain 2012;153(2):265‐8. [DOI: 10.1016/j.pain.2011.10.004] - DOI - PubMed
Moore 2013a
    1. Moore RA, Straube S, Aldington D. Pain measures and cut‐offs ‐ 'no worse than mild pain' as a simple, universal outcome. Anaesthesia 2013;68(4):400‐12. [DOI: 10.1111/anae.12148] - DOI - PubMed
Moore 2013b
    1. Moore A, Derry S, Eccleston C, Kalso E. Expect analgesic failure; pursue analgesic success. BMJ 2013;346:f2690. [DOI: 10.1136/bmj.f2690] - DOI - PubMed
Moore 2014a
    1. Moore RA, Derry S, Taylor RS, Straube S, Phillips CJ. The costs and consequences of adequately managed chronic non‐cancer pain and chronic neuropathic pain. Pain Practice 2014;14(1):79‐94. [DOI: 10.1111/papr.12050] - DOI - PubMed
Moore 2014b
    1. Moore RA, Wiffen PJ, Derry S, Toelle T, Rice AS. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2014, Issue 4. [DOI: 10.1002/14651858.CD007938.pub3] - DOI - PMC - PubMed
Moore 2014c
    1. Moore RA, Cai N, Skljarevski V, Tölle TR. Duloxetine use in chronic painful conditions ‐ individual patient data responder analysis. European Journal of Pain 2014;18(1):67‐75. [DOI: 10.1002/j.1532-2149.2013.00341.x] - DOI - PMC - PubMed
Moore 2015
    1. Moore RA, Wiffen PJ, Eccleston C, Derry S, Baron R, Bell RF, et al. Systematic review of enriched‐enrolment randomised‐withdrawal trial designs in chronic pain: a new framework for design and reporting. Pain 2015 [Epub]. [DOI: 10.1097/j.pain.0000000000000088] - DOI - PubMed
Mork 2010
    1. Mork PJ, Vasseljen O, Nilsen TI. Association between physical exercise, body mass index, and risk of fibromyalgia: longitudinal data from the Norwegian Nord‐Trøndelag Health Study. Arthritis Care & Research 2010;62:611‐7. [DOI: 10.1002/acr.20118] - DOI - PubMed
O'Brien 2010
    1. O'Brien EM, Staud RM, Hassinger AD, McCulloch RC, Craggs JG, Atchison JW, et al. Patient‐centered perspective on treatment outcomes in chronic pain. Pain Medicine 2010;11(1):6‐15. [DOI: 10.1111/j.1526-4637.2009.00685.x] - DOI - PubMed
Oaklander 2013
    1. Oaklander AL, Herzog ZD, Downs HM, Klein MM. Objective evidence that small‐fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia. Pain 2013;154:2310‐6. [DOI: 10.1016/j.pain.2013.06.001] - DOI - PMC - PubMed
PaPaS 2012
    1. PaPaS author and referee guidance. papas.cochrane.org/papas‐documents (accessed 16 March 2016).
Queiroz 2013
    1. Queiroz LP. Worldwide epidemiology of fibromyalgia. Current Pain and Headache Reports 2013;17(8):356. [DOI: 10.1007/s11916-013-0356-5] - DOI - PubMed
RevMan 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Sommer 2012
    1. Sommer C, Häuser W, Burgmer M, Engelhardt R, Gerhold K, Petzke F, et al. Etiology and pathophysiology of fibromyalgia syndrome. Schmerz 2012;26:259‐67. [DOI: 10.1007/s00482-012-1174-0] - DOI - PubMed
Straube 2008
    1. Straube S, Derry S, McQuay HJ, Moore RA. Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. British Journal of Clinical Pharmacology 2008;66(2):266‐75. [DOI: 10.1111/j.1365-2125.2008.03200.x] - DOI - PMC - PubMed
Straube 2010a
    1. Straube S, Derry S, Moore RA, Paine J, McQuay HJ. Pregabalin in fibromyalgia ‐ responder analysis from individual patient data. BMC Musculoskeletal Disorders 2010;11:150. [DOI: 10.1186/1471-2474-11-150] - DOI - PMC - PubMed
Straube 2010b
    1. Straube S, Derry S, Moore RA, McQuay HJ. Pregabalin in fibromyalgia: meta‐analysis of efficacy and safety from company clinical trial reports. Rheumatology (Oxford) 2010;49(4):706‐15. [DOI: 10.1093/rheumatology/kep432] - DOI - PubMed
Straube 2011
    1. Straube S, Moore RA, Paine J, Derry S, Phillips CJ, Hallier E, et al. Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response. BMC Musculoskeletal Disorders 2011;12:125. [DOI: 10.1186/1471-2474-12-125] - DOI - PMC - PubMed
Sultan 2008
    1. Sultan A, Gaskell H, Derry S, Moore RA. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurology 2008;8:29. [DOI: 10.1186/1471-2377-8-29] - DOI - PMC - PubMed
Taylor 2007
    1. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2‐delta (alpha2‐delta) subunit as a target for antiepileptic drug discovery. Epilepsy Research 2007;73(2):137‐50. [DOI: 10.1016/j.eplepsyres.2006.09.008] - DOI - PubMed
Tzellos 2010
    1. Tzellos TG, Toulis KA, Goulis DG, Papazisis G, Zampeli VA, Vakfari A, et al. Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta‐analysis. Journal of Clinical Pharmacology and Therapeutics 2010;35(6):239‐56. [DOI: 10.1111/j.1365-2710.2009.01144.x] - DOI - PubMed
Vos 2012
    1. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet 2012;380(9859):2163‐96. [DOI: 10.1016/S0140-6736(12)61729-2] - DOI - PMC - PubMed
Walitt 2015
    1. Walitt B, Nahin RL, Katz RS, Bergman MJ, Wolfe F. The prevalence and characteristics of fibromyalgia in the 2012 National Health Interview Survey. PLoS One 2015;10(9):e0138024. [DOI: 10.1371/journal.pone.0138024] - DOI - PMC - PubMed
Wiffen 2013
    1. Wiffen PJ, Derry S, Moore RA, Aldington D, Cole P, Rice ASC, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia ‐ an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 2013, Issue 11. [DOI: 10.1002/14651858.CD010567.pub2] - DOI - PMC - PubMed
Wolfe 1990
    1. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis and Rheumatism 1990;33(2):160‐72. [DOI: 10.1002/art.1780330203] - DOI - PubMed
Wolfe 2010
    1. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care and Research 2010;62(5):600‐10. [DOI: 10.1002/acr.20140] - DOI - PubMed
Wolfe 2011
    1. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RS, et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. Journal of Rheumatology 2011;38:1113‐22. [DOI: 10.3899/jrheum.100594] - DOI - PubMed
Wolfe 2012
    1. Wolfe F, Walitt BT, Katz RS, Lee YC, Michaud KD, Häuser W. Longitudinal patterns of analgesic and central acting drug use and associated effectiveness in fibromyalgia. European Journal of Pain 2013;17(4):581‐6. [DOI: 10.1002/j.1532-2149.2012.00234.x] - DOI - PubMed
Wolfe 2013
    1. Wolfe F, Brähler E, Hinz A, Häuser W. Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: results from a survey of the general population. Arthritis Care and Research 2013;645(5):777‐85. [DOI: 10.1002/acr.21931] - DOI - PubMed
Wolfe 2014
    1. Wolfe F, Walitt BT, Häuser W. What is fibromyalgia, how is it diagnosed and what does it really mean?. Arthritis Care and Research 2014;66(7):969‐71. [DOI: 10.1002/acr.22207] - DOI - PubMed
Yunus 2008
    1. Yunus MB. Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness. Seminars in Arthritis and Rheumatism 2008;37:339‐52. [DOI: 10.1016/j.semarthrit.2007.09.003] - DOI - PubMed
Üçeyler 2013a
    1. Üçeyler N, Zeller D, Kahn AK, Kewenig S, Kittel‐Schneider S, Schmid A, et al. Small fibre pathology in patients with fibromyalgia syndrome. Brain 2013;136:e247. [DOI: 10.1093/brain/awt053] - DOI - PubMed
Üçeyler 2013b
    1. Üçeyler N, Sommer C, Walitt B, Häuser W. Anticonvulsants for fibromyalgia. Cochrane Database of Systematic Reviews 2013, Issue 10. [DOI: 10.1002/14651858.CD010782] - DOI - PubMed

References to other published versions of this review

Moore 2009
    1. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007076.pub2] - DOI - PMC - PubMed

LinkOut - more resources